Specialized fat-and-oil emulsion food systems for the prevention of hyperlipidemia and obesity
AbstractThe development of specialized fat-and-oil emulsion food systems for the prevention of hyperlipidemia and obesity is an important task of health concern in the Russian Federation.
The aim of the study was to develop specialized fat-and-oil emulsion food systems for the prevention of hyperlipidemia and obesity, the distinctive features of which are the presence of functional ingredients and bioactive compounds that meet modern safety requirements, have a hypolipidemic effect and influence on body weight.
Material and methods. As a source of fucoxanthin, an oil extract from the thallom (stratum) of the annual Undaria pinnatifida brown algae was used, obtained by re-extraction with soy oil for 8 hours from a glycerin extract (extractant – 60% glycerin solution, the duration of the process – 8 h). The determination of organoleptic parameters was carried out at a temperature of 20 °C 12 h after manufacture using standard methods. Organoleptic parameters were determined in the following sequence: consistency, appearance, color, smell, taste. Physical and chemical characteristics (mass content of fat, moisture, egg products in terms of dry yolk, acidity in terms of acetic acid, emulsion stability), acid and peroxide values were studied by standard methods. Fatty acid analysis of lipids was performed by gas-liquid chromatography. The fucoxanthin content was determined by spectrophotometric method.
Results. The presented formulations of lipid compositions as the fat base of specialized oil-fat emulsion food systems for the prevention of hyperlipidemia and obesity included Schizochytrium sp. microalgae oil in a mass fraction of 3–6% as a source of ω-3 polyunsaturated fatty acids (PUFAs) (eicosapentaenoic and docosahexaenoic acids). An oil extract of U. pinnatifida brown algae in a mass fraction of 48–54% was used as a source of fucoxanthin. The total content of PUFA was significantly high – at least 73%, ω-6 PUFA prevailed (48.0–49.1%). However, the high content of ω-3 PUFA (at least 25%) should be also noted. The ratio of ω-3 to ω-6 PUFA was 1:1.72–1:1.90, which is atypical for individual vegetable oils traditionally used as the fat phase in fat-and-oil emulsion systems. The fucoxanthin content in the presented lipid compositions was 6.4–7.2 mg/100 ml. Edible fat-and-oil emulsion food systems for the prevention of hyperlipidemia and obesity (mayonnaise and mayonnaise sauces) with a given ratio of ω-3:ω-6 PUFA containing eicosopentaenoic and docosahexaenoic acids, as well as fucoxanthin, have been obtained. The extract of U. pinnatifida brown algae, containing fucoxanthin, significantly slowed down the processes of lipid oxidation and hydrolysis, as evidenced by changes in the peroxide and acid values of fat isolated from specialized fat-and-oil emulsion systems for the prevention of hyperlipidemia and obesity.
Conclusion. Specialized fat-and-oil emulsion food systems for the prevention of hyperlipidemia and obesity (mayonnaise and mayonnaise sauces with different oil phase content), containing fucoxanthin, having an optimized fatty acid composition, a given ratio of ω-3:ω-6 PUFA, high content of essential PUFA (eicosopentaenoic and docosohexaenoic acids) are safe food products with traditional organoleptic characteristics and specified physical and chemical parameters.
Keywords:fucoxanthin; eicosopentaenoic acid; docosahexaenoic acid; fat-and-oil emulsion product; hyperlipidemia; obesity
Funding. The research was carried out with the financial support of the Russian Science Foundation (grant 22-76-00008), https://rscf.ru/project/22-76-00008/.
Conflict of interest. The authors declare no conflict of interest.
Contribution The authors declare an equal contribution in the preparation of the article.
For citation: Tabakaev A.V., Tabakaeva O.V. Specialized fat-and-oil emulsion food systems for the prevention of hyperlipidemia and obesity. Voprosy pitaniia [Problems of Nutrition]. 2024; 93 (2): 83–94. DOI: https://doi.org/10.33029/0042-8833-2024-93-2-83-94 (in Russian)
References
1. Kuipers R.S., de Graaf D.J., Luxwolda M.F., Muskiet M.H., Dijck-Brouwer D.A., Muskiet F.A. Saturated fat, carbohydrates and cardiovascular disease. Neth J Med. 2011; 69 (9): 372–8. PMID: 21978979.
2. Kim S.M., Jung Y.H., Kwon O., Cha K.H., Um B.H. A potential commercial source of fucoxanthin extracted from the microalga Phaeodactylum tricornutum. Appl Biochem Biotechnol. 2012; 166: 1843–55. DOI: https://doi.org/10.1007/s12010-012-9602-2
3. Maoka T. Carotenoids as natural functional pigments. J Nat Med. 2020; 74 (1): 1–16. DOI: https://doi.org/10.1007/s11418-019-01364-x
4. Grebnev D.Yu., Maklakova I.Yu., Titova D.I., Permyakov N.S. Geroprotective properties of fucoxanthin. Ural Medical Journal. 2022; 21 (5): 94–101. DOI: http://doi.org/10.52420/2071-5943-2022-21-5-94-101 (in Russian)
5. Ahmed S.A., Mendonca P., Elhag R., Soliman K.F.A. Anticancer effects of fucoxanthin through cell cycle arrest, apoptosis induction, angiogenesis inhibition, and autophagy modulation. Int J Mol Sci. 2022; 23: 16091. DOI: https://doi.org/10.3390/ijms232416091
6. Lopes F.G., Oliveira K.A., Lopes R.G., Poluceno G.G., Simioni C., Gabriel D.S.P., et al. Anti-cancer effects of fucoxanthin on human glioblastoma cell line. Anticancer Res. 2020; 40 (12): 6799–815. DOI: https://doi.org/10.21873/anticanres.14703
7. Méresse S., Fodil M., Fleury F., Chénais B. Fucoxanthin, a marine-derived carotenoid from brown seaweeds and microalgae: A promising bioactive compound for cancer therapy. Int J Mol Sci. 2020; 21 (3): 9273. DOI: https://doi.org/10.3390/ijms21239273
8. Jang H., Choi J., Park J.-K., Won G., Seol J.-W. Fucoxanthin exerts anti-tumor activity on canine mammary tumor cells via tumor cell apoptosis induction and angiogenesis inhibition. Animals. 2021; 11: 1512. DOI: https://doi.org/10.3390/ani11061512
9. Ahmed S.A., Mendonca P., Messeha S.S., Soliman K.F.A. Anticancer effects of fucoxanthin through cell cycle arrest, apoptosis induction, and angiogenesis inhibition in triple-negative breast cancer cells. Molecules. 2023; 28: 6536. DOI: https://doi.org/10.3390/molecules2818653610
10. Liu M., Li W., Chen Y., Wan X., Wang J. Fucoxanthin: A promising compound for human inflammation-related diseases. Life Sci. 2020; 255: 117850. DOI: https://doi.org/10.1016/j.lfs.2020.117850
11. Oliyaei N., Moosavi-Nasab M., Tamaddon A.M., Tanideh N. Antidiabetic effect of fucoxanthin extracted from sargassumangustifolium on streptozotocin-nicotinamide-induced type 2 diabetic mice. Food Sci Nutr. 2021; 9: 3521–9. DOI: https://doi.org/10.1002/fsn3.2301
12. Qiu S., Shen Y., Wu Z., Zhang X., Ge S. Effects of algae subtype and extraction condition on extracted fucoxanthin antioxidant property: A 20-year meta-analysis. Algal Research. 2021; 53: 102161. DOI: https://doi.org/10.1016/j.algal.2020.102161
13. Bae M., Kim M.-B., Park Y.-K., Lee J.-Y. Health benefits of fucoxanthin in the prevention of chronic diseases. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 2020; 1865 (11): 158618. DOI: https://doi.org/10.1016/j.bbalip.2020.158618
14. Miyashita K., Beppu F., Hosokawa M., Liu X., Wang S. Nutraceutical characteristics of the brown seaweed carotenoid fucoxanthin. Arch Biochem Biophys. 2020; 686: 108364. DOI: https://doi.org/10.1016/j.abb.2020.108364
15. Mohibbullah M., Haque M.N., Sohag A.A.M., Hossain M.T., Zahan M.S., Uddin M.J., et al. A systematic review on marine algae-derived fucoxanthin: An update of pharmacological insights. Marine Drugs. 2022; 20 (5): 279. DOI: https://doi.org/10.3390/md20050279
16. Hu X., Li Y., Li C., Fu Y., Cai F., Chen Q., Li D. Combination of fucoxanthin and conjugated linoleic acid attenuates body weight gain and improves lipid metabolism in high-fat diet-induced obese rats. Arch. Biochem Biophys. 2012; 519: 59–65. DOI: https://doi.org/10.1016/j.abb.2012.01.011
17. Tong L. Acetyl-coenzyme A carboxylase: Crucial metabolic enzyme and attractive target for drug discovery. Cell. Mol. Life Sci. 2005; 62: 1784–803. DOI: https://doi.org/10.1007/s00018-005-5121-4
18. Beppu F., Hosokawa M., Niwano Y., Miyashita K. Effects of dietary fucoxanthin on cholesterol metabolism in diabetic/obese KK-A(y) mice. Lipids Health Dis. 2012; 11: 112. DOI: https://doi.org/10.1186/1476-511X-11-112
19. Dandona P., Aljada A., Chaudhuri A., Mohanty P., Garg R. Metabolic syndrome: A comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005; 111: 1448–54. DOI: https://doi.org/10.1161/01.CIR.0000158483.13093.9D
20. Karkhaneh Y., Hashtroudi S., Mashinchian M., Ghassempour A.R. Seasonal variation of fucoxanthin content in four species of brown seaweeds from Qeshm Island, Persian Gulf and evaluation of their antibacterial and antioxidant activities. Iranian Journal of Fisheries Sciences. 2020; 19 (5): 2394–409. DOI: https://doi.org/10.22092/ijfs.2020.122396
21. Zarekarizi A., Hoffmann L., Burritt D. Approaches for the sustainable production of fucoxanthin, a xanthophyll with potential health benefits. J Appl Phycol. 2019; 31: 281–99. DOI: https://doi.org/10.1007/s10811-018-1558-3
22. Sato A., Kawano H., Notsu T., Ohta M., Nakakuki M., Mizuguchi K., et al. Antiobesity effect of eicosapentaenoic acid in high-fath/high-sucrose diet–induced obesity. Diabetes. 2010; 59 (10): 2495–504. DOI: https://doi.org/10.2337/db09-1554
23. Pahlavani M., Ramalingam L., Miller E.K., Davis H., Scoggin S., Moustaid-Moussa N. Discordant dose-dependent metabolic effects of eicosapentanoic acid in diet-induced obese mice Nutrients. 2020; 12 (5): 1342. DOI: https://doi.org/10.3390/nu12051342
24. Albracht-Schulte K., Gonzalez S., Jackson A., Wilson S., Ramalingam L., Kalupahana N.S., Moustaid-Moussa N. Eicosapentaenoic acid improves hepatic metabolism and reduces inflammation independent of obesity in high-fat-fed mice and in hepG2 cells. Nutrients. 2019; 11 (3): 599. DOI: https://doi.org/10.3390/nu11030599
25. Wei W., Hu M., Huang J., Yu S., Li X., Li Y., Mao L. Anti-obesity effects of DHA and EPA in high fat-induced insulin resistant mice. Food Funct. 2021; 12 (4): 1614–25. DOI: https://doi.org/10.1039/d0fo02448a
26. Zhuang P., Lu Y., Shou Q., Mao L., He L., Wang J., et al. Differential anti-adipogenic effects of eicosapentaenoic and docosahexaenoic acids in obesity. Mol Nutr Food Res. 2019; 63 (14): 1801135. DOI: https://doi.org/10.1002/mnfr.201801135
27. Zhang H.-J., Gao X., Guo X.-F., Li K-L., Li S., Sinclair A.J., Li D. Effects of dietary eicosapentaenoic acid and docosahexaenoic acid supplementation on metabolic syndrome: A systematic review and meta-analysis of data from 33 randomized controlled trials. Clin Nutr. 2021; 40 (7): 4538–50. DOI: https://doi.org/10.1016/j.clnu.2021.05.025
28. Tabakaev A.V., Tabakaeva O.V., Prihod’ko Yu.V. The study of consumer interest in specialized food systems for the prevention of an alimentary-dependent socially significant disease – obesity. Tekhnologiya i tovarovedenie innovatsionnykh pishchevykh produktov [Technology and Commodity Science of Innovative Food Products]. 2023; (1): 94–101. DOI: https://doi.org/10.33979/2219-8466-2023-78-6-94-101 (in Russian)
29. Sukhoveeva M.V., Podkorytova A.V. Commercial algae and grasses of the seas of the Far East: biology, distribution, reserves, processing technology Vladivostok: TINRO Center; 2006: 243 р. ISBN 5-89131-055-4 (in Russian)
30. Nechaev A.P. Mayonnaise. St Petersburg: GIORD; 2000: 80 p. ISBN 5-901065-17-4. (in Russian)
31. Tabakaev A.V., Tabakaeva O.V., Prihod’ko Yu.V. Method for obtaining xanthophylls from Undaria pinnatifida Patent for invention 2789359 C1, 02.02.2023. Application No. 2022106456 dated 03/14/2022. (in Russian)
32. Tabakaev A.V., Tabakaeva O.V. Comparative characteristics of carotenoid profiles and antiradical properties of extracts of brown kelp from the Sea of Japan. Chem Nat Compd. 2022; 58 (2): 352–4. DOI: https://doi.org/10.1007/s10600-022-03678-x
33. Narayani S., Saravanan S., Bharathiraja S., Mahendran S. Extraction, partially purification and study on antioxidant property of fucoxanthin from Sargassum cinereum. J Agardh Pharm Res. 2016; 8 (3): 610–6. DOI: https://doi.org/10.17844/jphpi.v20i2.18105
34. Novak I.S. Quantitative analysis by gas chromatography. Moscow: Mir; 1978: 180 p. (in Russian)
35. Carreau J.P., Dubacq J.P. Adaptation of a macro-scale method to the micro-scale for fatty acid methyl transesterification of biological lipid extracts. J Chromatogr. 1978; 151: 384–90.
36. Sizova N.V., Pikuleva I.V., Chikunova T.M. Fatty acid composition of Camelina sativa (L.) Crantz oil and selection of optimal antioxidant. Khimija Rastitel’nogo Syr’ja [Chemistry of Plant Raw Material]. 2003; 2: 27–31. (in Russian)
37. Abidov M., Ramazanov Z., Seifulla R., Grachev S. The effects of Xanthigen in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fat. Diabetes Obes Metab. 2010; 12: 72–81. DOI: https://doi.org/10.1111/j.1463-1326.2009.01132.x
38. Din N.A.S., Mohd Alayudin ‘A.S., Sofian-Seng N-S., Rahman H.A., Mohd Razali N.S., Lim S.J., et al. Brown algae as functional food source of Fucoxanthin: A review. Foods. 2022; 11 (5): 2235. DOI: https://doi.org/10.3390/foods11152235